$Cidara Therapeutics(CDTX.US)$ NEWS Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 Cidara Therapeutics announced data presentations at ESCMID 2024 on CD388, highlighting Phase 1 and Phase 2a clinical data. The Phase 2a study showed CD388 was well-tolerated with significant antiviral effects in healthy volunteers challenged with influenza. The Phase 1 study demonstrated an extended half-life of 6-8 weeks, indicating potential f...
$Cidara Therapeutics(CDTX.US)$Cidara Therapeutics To Sell Candidiasis Treatment, Re-acquire Flu Asset WSJ· 4 mins ago Cidara Therapeutics said it would sell its candidiasis treatment rezafungin to its partner and buy back the license to its potential influenza-prevention treatment. The San Diego-based biotechnology company said Wednesday that it was divesting the treatment, sold under the brand name Rezzayo, t...
$Cidara Therapeutics(CDTX.US)$Cidara Therapeutics- for Exclusive Global Development, Commercial Rights to Cd388, Johnson & Johnson Got One-Time Upfront Payment of $85 Mln From Co
Cidara Therapeutics股票討論區
Dow Jones· 1 min ago
NEWS
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
Cidara Therapeutics announced data presentations at ESCMID 2024 on CD388, highlighting Phase 1 and Phase 2a clinical data. The Phase 2a study showed CD388 was well-tolerated with significant antiviral effects in healthy volunteers challenged with influenza. The Phase 1 study demonstrated an extended half-life of 6-8 weeks, indicating potential f...
Larger Image: tradingview.com...
$Cidara Therapeutics(CDTX.US)$
Hopefully it'll continue to run tomorrow?
WSJ· 4 mins ago
Cidara Therapeutics said it would sell its candidiasis treatment rezafungin to its partner and buy back the license to its potential influenza-prevention treatment.
The San Diego-based biotechnology company said Wednesday that it was divesting the treatment, sold under the brand name Rezzayo, t...
暫無評論